牛磺酸对急性低氧促培养的兔肺小动脉平滑肌细胞产生血栓素A2和前列环素的影响

本工作观察了牛磺酸（taurine）对分离培养家兔肺小动脉平滑肌细胞（PASMCs）在急性低氧条件下培养液中血栓素B2（TxB2）和6-酮-前列腺素F1α（6-keto-PGF1α）含量及其比值变化的影响,同时用环加氧酶抑制剂吲哚美辛干预,以探讨牛磺酸的作用途径。结果是：低氧使PASMCs培养液中TxB2和6-keto－PGF1α含量及其比值显著增加。常氧和低氧条件下,终浓度为2．5×10-5mol／L的牛磺酸显著降低TxB2的含量;显著提高6-keto-PGF1α的含量,终浓度为2．5×10－3mol／L的吲哚美辛显著降低TxB2和6-keto-PGF1α含量,牛磺酸和吲哚美辛共同作用,TxB2的含量进一步降低,6－keto-PGF1α含量比单纯用吲哚美辛增加明显。这些结果表明,牛磺酸可能通过抑制PASMCs内的TxA2合成酶的活性和增强前列环素（PGI2）合成酶的活性拮抗低氧增强PASMCs产生TxA2和PGI2,使TxA2与PGI2的比值显著降低而逆转低氧性肺血管收缩。     

红花注射液对慢性低O2高CO2肺动脉高压的影响

目的：探讨红花注射液对大鼠在慢性低O2高CO2下肺动脉高压的抑制作用。方法：将SD大鼠分为对照组,慢性低O2高CO2组,慢性低O2高CO2＋红花注射液组。用电镜、放免等方法,观察各组大鼠肺动脉平均压、颈动脉平均压、肺细小动脉显微结构、血浆和肺匀浆TXB2及6-keto-PGF1a含量的变化。结果：①慢性低O2高CO2组mPAP比对照组显著增高,红花注射液组的mPAP比慢性低O2高CO2组显著降低,3组间mCAP比较差异无显著性。②慢性低O2高CO2组与对照组相比血浆和肺匀浆TXB2浓度、TXB2／6-keto-PGF1a比值显著增高,6-keto-PGF1a浓度显著下降;红花注射液组与慢性低P2高CO2相比血浆和肺匀浆TXB2浓度、TXB2／6-keto-PGF1a显著下降,6-keto-PGF1a显著升高。③光镜下慢性低O2高CO2组与对照组相比,肺细小动脉管壁面积／管总面积（WA／TA）和肺细小动脉中膜厚度（PAMT）均显著增高。红花注射液组WA／TA和PAMT显著降低。④电镜下慢性低O2高CO2组大鼠肺细小动脉内皮细胞吞饮小泡增多,血管壁增厚,中膜平滑肌细胞增生,纤维细胞增多,肺泡Ⅱ型上皮细胞微绒毛脱落;红花注射液组肺细小动脉中膜平滑肌细胞增生减轻,纤维细胞少,胶原纤维减少,肺泡Ⅱ型上皮细胞微绒毛丰富、结构清。结论：红花注射液有减轻慢性低O2高CO2性肺动脉高压和肺血管结构重建的作用,可能与抑制TXA2的合成,保护血管内皮细胞,使TXA2/PGI2比值降低有关.     

油酸所致急性肺水肿机制的研究

为了探讨呼吸窘迫综合征（Respiratory Distress Syndrome简称RDS）时急性肺水肿的机制,我们应用静脉注射油酸引起RDS模型研究的肺血管及血管内皮细胞的损伤变化。我们的实验发现肺损伤后系数明显升高,证实油酸引起肺损伤早期确实存在急性肺水肿;肺微血管面积密度增大定量反映肺组织中血管扩张,充血;血浆6-酮-PGF1α和TxB2含量变化以及Ｐ／Ｔ比值呈增加趋势提示该变化与血扩张有密切关系;血清ACE活性升高表明血管内皮细胞膜受到损伤;此外形态学观察也发现血内皮细胞有形态及功能改变,提示血管内皮细胞是 引起急性肺水肿更直接的原因。     

缺血预适应对肢体缺血/再灌注骨骼肌、小肠和肺损伤的影响

目的:观察肢体缺血/再灌注(LI/R)后骨骼肌、小肠、肺功能损伤变化,并探讨缺血预适应(IPC)的保护效应及机制。方法:实验用雄性Wistar大鼠24只,随机分为3组(n=8):对照(Control)组,缺血/再灌注(I/R)组和缺血预适应(IPC+I/R)组。分别测定血浆乳酸脱氢酶(LDH)、肌酸激酶(CK)、活性氧(ROS)、丙二醛(MDA)、动脉血氧分压(PaO2)和二氧化碳分压(PaCO2),测定血浆血栓素B2(TXB2),6-酮-前列腺素F1α(6-keto-PGF1α)的含量以及TXB2/6-keto-PGF1α比值的变化;测定骨骼肌、小肠、肺组织髓过氧化物酶(MPO)含量,肺湿干比(W/D)及小肠组织DAO含量。观察骨骼肌组织的形态学变化。结果:IPC+I/R组血浆LDH、CK、ROS、MDA、TXB2/6-keto-PGF1α比值明显低于I/R组,PaO2较I/R组明显升高。IPC+I/R组肺湿干比(W/D),骨骼肌、肺、小肠组织MPO含量明显低于I/R组,而小肠DAO活性升高。骨骼肌组织病理学改变减轻。结论:缺血预适应减轻了缺血/再灌注后骨骼肌、小肠、肺功能的损伤,其机制可能与降低氧化损伤、改善TXB2/6-keto-PGF1α的平衡关系有关。     

大鼠脑缺血-再灌注前后血浆TXB2及6-Keto-PGF1α含量的变化

目的:本实验旨在揭示脑缺血-再灌注损伤前后大鼠血浆血栓素B2(TXB2)及6-酮前列腺环素F1(6-Keto-PGF1α)的动态变化.方法:制作脑缺血-再灌注大鼠模型,45只健康SD大鼠随机分为正常对照组、模型组和假手术组大鼠.在术后1天、3天、5天和7天分别观察大鼠血浆TXB2和6-Keto-PGF1α含量.结果:线栓大脑中动脉后造成脑缺血,血浆TXB2含量和TXB2/6-Keto-PGF1α比值明显高于假手术组和正常对照组(p＜0.05或0.01),在缺血第1天最显著.结论:脑缺血-再灌注损伤后,血浆TXB2和TXB2/6-Keto-PGF1α的变化规律可为临床缺血性脑损伤治疗提供重要参考.     

塞来昔布对慢性低O_2高CO_2大鼠肺动脉高压的影响及其机制研究

目的：探讨塞来昔布对慢性低O2高CO2大鼠肺动脉高压的作用。方法：将SD大鼠分为正常对照组,慢性低O2高CO2组,慢性低O2高CO2＋塞来昔布组。用电镜、放免等方法,观察各组大鼠肺动脉平均压、颈动脉平均压、肺细小动脉显微结构、血浆和肺匀浆血栓素B2（TXB2）及6-酮-前列腺素F1α（6-keto-PGF1α）含量的变化。结果：①慢性低O2高CO2组平均肺动脉压（mPAP）比正常组显著升高,塞来昔布组的mPAP比慢性低O2高CO2组显著升高,3组间平均颈动脉压（mCAP）比较差异无显著性。②慢性低O2高CO2组与正常对照组相比血浆和肺匀浆TXB2浓度、TXB2/6-keto-PGF1α比值显著增高,6-keto-PGF1α浓度显著下降;塞来昔布组与慢性低O2高CO2组相比血浆和肺匀浆TXB2浓度无明显变化、TXB2/6-keto-PGF1α显著升高,6-keto-PGF1α显著下降。③光镜下慢性低O2高CO2组与正常组相比,肺细小动脉管壁面积/管总面积（WA/TA）和肺细小动脉中膜厚度（PAMT）均显著增高。塞来昔布组与慢性低O2高CO2组相比WA/TA和PAMT显著增高。④电镜下慢性低O2高CO2组大鼠肺细小动脉内皮细胞吞饮小泡增多,血管壁增厚,中膜平滑肌细胞增生,纤维细胞增多,肺泡II型上皮细胞微绒毛脱落;塞来昔布组中膜平滑肌细胞增大、增多,胞浆肌丝丰富,平滑肌细胞间隙增宽,肺泡隔胶原纤维增生明显。结论：塞来昔布可能有加重慢性低O2高CO2性肺动脉高压和肺血管结构重建倾向,过度抑制COX-2,使TXA2/PGI2比值升高可能是其作用机制之一。     

白藜芦醇苷对血栓形成及血浆TXB2和6-keto-PGF1α水平的影响

研究了白藜芦醇苷(polydatim,PD)的抗血栓形成作用及其作用机制。采用小鼠尾静脉注射花生四烯酸(arachidonicacid,AA)、电刺激大鼠颈动脉血栓形成方法评价PD的抗血栓形成作用;运用放射免疫法测定polydatin对兔血浆血栓素B2(thromboxaneB2,TXB2)及6酮前列腺素F1α(6ketoprostaglandinF1α,6ketoPGF1α)水平的影响。结果显示PD对AA、电刺激大鼠颈动脉引起的血栓形成具有明显的对抗作用;PD亦能降低兔血浆TXB2含量并升高6KetoPGF1α水平。本实验提示PD有明显的抗血栓形成作用,其机制可能与其降低血浆TXB2含量及升高6KetoPGF1α水平密切相关。     

降气止血汤辅助法莫替丁对消化性溃疡急性出血患儿TXB2、6-Keto-PGF1α水平的影响

目的:探究降气止血汤辅助法莫替丁对消化性溃疡急性出血患儿血浆血栓烷B2 (Thromboxane B2, TXB2)、6-酮前列腺素(6-keto-prostaglandin, 6-Keto-PGF1α)水平的影响。方法:选择我院2015年10月-2018年10月收治的60例消化性溃疡急性出血患儿,经随机数字表法分为两组,每组30例。对照组采用法莫替丁进行治疗,研究组在对照组基础上联合降气止血汤进行治疗。对比两组的治疗总有效率、治疗前后凝血功能指标和TXB2、6-Keto-PGF1α水平的变化。结果:治疗后,研究组的治疗总有效率显著高于对照组(P0.05);两组的凝血酶时间(Thrombin time, TT)、凝血酶原时间(Prothrombin time, PT)、凝血活酶时间(activated partial thromboplastin time, aPTT)及6-Keto-PGF1α水平均显著低于治疗前,血小板计数(Platelet count, PLT)、纤维蛋白原(Fibrinogen,Fbg)及TXB2水平均明显高于治疗前,且研究组以上指标改善更明显(P0.05)。结论:降气止血汤辅助法莫替丁治疗消化性溃疡急性出血患儿的效果显著优于单用法莫替丁治疗,可能与其有效改善患儿的凝血功能及TXB2和6-Keto-PGF1α水平有关。     

改善血栓形成新的药物组合物及其分子机制

目的：研究α1受体阻断药与山莨菪碱（Ani）形成的药物组合物改善血栓形成的作用及其分子机制。方法：离体大鼠尾动脉血管模型研究α1受体阻断药及其与山莨菪碱的药物组合物的扩血管效应,角又菜胶诱发小鼠尾部血栓模型研究组合物对抗血栓形成的作用及其机制。结果：α1受体阻断药中哌唑嗪（Pra）对血管环舒张率最大,达（82．6±8．9）％,作用强度最强,Ec50值为O．44μmol/L;山莨菪碱和哌唑嗪分别以不同剂量配伍组成组合物,能使角叉菜胶诱发的鼠尾血栓长度（啪）由24．6±4．6缩短到6．94-2．7,成栓率由86．6％下降到50．0％。上述新药物组合物能显著延长血栓小鼠血浆凝血酶原时间（er）,对活化部分凝血活酶时间（APTT）无影响;能抑制血栓小鼠血浆中组织型纤溶酶原激活剂（t-PA）、6-酮一前列腺素F1a（6．Keto．PGF1α）含量的降低和组织纤溶酶原激活剂抑制物-1（PAI-1）、血栓烷B2（TXB2）的增多;并不在于扩血管作用的进一步增强上。结论：山莨菪碱和哌唑嗪组成的药物组合物具有舒张外周血管和改善血栓形成的作用,其抗血栓形成机制分别与影响外源性凝血途径、抑制血小板的活化功能以及促进纤溶功能有关。     

急性低氧和间断低氧习服对HepG2细胞内血管内皮细胞生长因子基因表达的影响

目的:观察急性低氧和间断低氧习服对人HepG2细胞内血管内皮细胞生长因子(VEGF)及转录因子低氧诱导因子-1α(HIF-1α)的mRNA和蛋白含量的影响及其可能的生物学意义.方法:HepG2细胞随机分为常氧对照组,急性低氧组和间断低氧习服组.采用Northern blot和Western blot分别检测不同组别HepG2细胞内VEGF和HIF-1α mRNA表达和蛋白含量的变化.结果:急性低氧诱导HepG2细胞内VEGF和HIF-1α基因的转录,增加两种蛋白在细胞内的含量.间断低氧习服组的细胞内VEGF和HIF-1α的mRNA含量分别为常氧对照组细胞的(108.6±17.7)%和(116.74±19.8)%,与常氧对照组相比无显著差异(P＞0.05);而其蛋白表达的含量分别为对照组细胞的1.4和2.7倍,都明显低于急性低氧组细胞内两种蛋白的含量(P＜0.05).结论:HepG2细胞达到低氧习服状态后,抑制急性低氧对HepG2细胞内VEGF基因表达的促进作用,其中HIF-1α可能起着重要的调节作用.     

Comparison of umbilical vein models for measurement of relative prostacyclin and thromboxane production

There is growing evidence that blood vessels generate TXA2 in addition to PGI2. We examined effluents from continuously perfused human umbilical vein and supernatants from umbilical vein rings for TXB2 and 6-keto-PGF1 alpha measurements (stable metabolites of TXA2 and PGI2, respectively). TXB2 and 6-keto-PGF1 alpha were identified in all samples. 6-keto-PGF1 alpha to TXB2 ratio was higher in intact vein effluents than in the venous ring supernatants (112:1 and 28:1, respectively, P less than 0.01). Arachidonate stimulation increased 6-keto-PGF1 alpha and TXB2 levels similarly in the intact vein effluent. In contrast, stimulation of the venous rings resulted in a relatively larger increase in TXB2 than in 6-keto-PGF1 alpha. This caused 6-keto-PGF1 alpha to TXB2 ratio to decline (p less than 0.01). The identity of TXB2 was confirmed in several different ways. These data suggest that 1) human umbilical veins produce TXA2 in addition to PGI2, 2) TXA2 release is more by venous rings than by the intact vein probably reflecting contribution from non-endothelial layers, and 3) arachidonate stimulation causes relatively greater release of TXA2 than of PGI2 from the venous rings, whereas release of PGI2 and TXA2 is similar from the intact vein.     

Myocardial prostacyclin and thromboxane A2 synthetase activities during ischemia and reperfusion in isolated rabbit heart

The aim of the study was to determine the prostacyclin (PGI2) and thromboxane A2 (TXA2) synthetase activities of myocardial tissue and their variation during ischemia and reperfusion. Regional ischemia was induced by 10 min occlusion of the left anterior descending coronary artery in isolated Langendorff rabbit hearts. Biosynthesis of PGI2 and TXA2 were carried out by using arachidonic acid as substrate and left ventricle microsomes (LVM) from ischemic and non-ischemic areas as sources of PGI2 and TXA2 synthetase. 6-keto-PGF1 alpha and TXB2, stable metabolites of PGI2 and TXA2 respectively, were determined by radioimmunoassay. Experiments carried out under the adopted conditions showed that LVM were able to synthetise PGI2 as well as TXA2 from arachidonic acid. On the other hand, ischemia depressed both PGI2 and TXA2 synthetase activities of cardiac tissue: the depression was more pronounced on TXA2 synthetase than on PGI2 synthetase with no significant difference between ischemic and non-ischemic regions. Moreover, ischemia increased the ratio 6-keto-PGF1 alpha/TXB2 indicating therefore that it can facilitate the formation of PGI2. The post ischemic reperfusion of the heart counteracted the decrease in PGI2 synthetase induced by ischemia which returned to the normal level: reperfusion also slightly reversed the decrease in TXA2 the decrease in TXA2 synthetase. However, the diminution in TXA2 synthetase of non-ischemic myocardium was attenuated but it remained lower than the normal level. These results suggested that the whole left ventricle is affected by regional ischemia. Furthermore it appears that myocardial TXA2 synthetase is more vulnerable than PGI2 synthetase to a lack of oxygen and nutrients.     

缺血缺氧再灌注对胎鼠肾组织环氧化酶表达的影响

目的观察宫内缺血缺氧再灌注后,胎鼠肾组织COX蛋白表达及其AA代谢产物PGI2、PGE2和TXA2含量的变化,探讨COX在宫内窘迫胎鼠肾损伤发病机制中的作用.方法制备胎鼠子宫内缺血缺氧再灌注模型(缺血缺氧组：缺血缺氧30min;再灌注组：缺血缺氧30min后,分别再灌注30min,2h,6h,12h,24h,30h)缺血氧组：取胎鼠18只;再灌注组各时间点分别取胎鼠18只;对照组取胎鼠20只.将肾组织匀浆后采用Western免疫印迹和放免法检测COX蛋白表达及其PGI2、PGE2和TXA2含量的变化.同时HE染色观察肾组织病理学改变.结果子宫内缺血缺氧再灌注后胎肾组织COX-2蛋白表达上调,PGI2的稳定代谢产物6-Keta-PGF1α及PGE2均于再灌注2h开始增高(P<0.05).其中6-keta-PGF1α增加迅速,于再灌注12h达假手术组的6倍(P<0.01),PGE2于再灌注24h达假手术组的2倍(P<0.01),而TXB2增加幅度不大,无统计学意义.结论宫内缺血缺氧再灌注选择性地诱导胎肾COX-2蛋白表达增强,COX-2可能通过PGI2和PGE2对缺血性胎肾损伤具有保护作用,因此,在围产期肾损伤不宜应用COX-2抑制剂.     

Correlation between dysmenorrheic severity and prostaglandin production in women with endometriosis.

The role of prostaglandins (PGs) in dysmenorrhea of endometriosis is poorly understood. The relationship between dysmenorrheic severity and prostaglandin production was investigated in endometriosis. Slices of normal myometrium, adenomyosis, normal ovary and endometrial cyst were incubated. 6-Keto-PGF1 alpha (a metabolite of PGI2), TXB2 (a metabolite of TXA2), PGF2 alpha, and PGE2 concentrations of the incubation medium were measured by RIA. The results showed that 6-keto-PGF1 alpha production in adenomyosis and endometrial cyst were significantly higher than those in normal myometrium and ovary. A direct relationship between the degree of dysmenorrheic severity and PGs production in tissue in endometriosis was observed.     

Decreased levels of prostaglandins I2 and E2 in acute gastric mucosal lesions induced by hypoxia

We have observed that the contents of prostaglandin (PG) D2 and 6-keto-PGF1 alpha were five times higher than those of PGE2 and PGF2 alpha in rat gastric mucosa. In order to elucidate the role of PGs in the function of gastric mucosa, we studied the effect of hypoxia on the levels of PGs in relation to the degree of gastric mucosal lesions. 6-Keto-PGF1 alpha levels were significantly decreased only by severe and long-term hypoxia (10% O2, 18 hours) when severe ulcerative lesions were observed. PGE2 levels were significantly decreased even by mild and short-term hypoxia (13% O2, 4 hours) when slight ulcerative lesions were observed. PGF2 alpha and PGD2 levels were significantly decreased by mild and short-term hypoxia; however, there was no significant difference from the control group under severe and long-term hypoxia. These results suggest that each of the PGs plays a different role in the pathogenesis of acute gastric mucosal lesions induced by hypoxia.     

Prostacyclin and thromboxane formation in human umbilical arteries following stimulation with vasoactive autacoids

The formation of prostacyclin (PGI2) and thromboxane A2 (TXA2) (measured as the stable metabolites 6-keto-PGF1 alpha and TXB2) during stimulation with vasoactive autacoids was registered in human umbilical arteries perfused in vitro. Responses were registered within 3-4 minutes after addition of the substances. Both angiotensin I and II were found to increase the formation of PGI2 while depressing that of TXA2. Serotonin increased the formation of TXA2 but not that of PGI2. Both PGE2 and PGF2 alpha stimulated the PGI2 formation. The TXA2 mimetic U46619, increased PGI2 production, whereas PGI2 slightly increased the formation of TXA2. All responses were found to be completely inhibited by indomethacin.     

Comparative effects of some 3-amino 4,6-diarylpyridazines on the biosynthesis in vitro of TXA2 and PGI2- and on the TXA2- and PGI2-synthesizing activities of cardiac tissue

Some 3-amino 4,6-diarylpyridazine derivatives were tested for their effects on TXA2 and PGI2 biosyntheses in vitro and on the TXA2- and PGI2-synthesizing activities of cardiac tissue. Horse platelet and aorta microsomes were used as sources of thromboxane and prostacyclin synthetases respectively. The TXA2- and PGI2-synthesizing activities of cardiac tissue were studied on isolated perfused rabbit hearts (the heart microsomes being used both as TXA2 synthetase and PGI2 synthetase sources). TXB2 and 6-keto PGF1 alpha were determined by RIA. Among the compounds under study, 3-morpholino 4,6-diphenylpyridazine (III) was shown to inhibit specifically the TXA2 synthetase. Substitution of the morpholino group by a dimethylamino one (I) reinforced the inhibiting effects on TXA2 synthetase but it also revealed a slight anti-prostacyclin synthetase action of the molecule. Replacement of 3-morpholino moieties by either a 3-hydrazino (IV), or a 2-dimethylaminoethylamino (V), or a 2-morpholinoethylamino group (VI) abolished completely the effects of the molecule on TXA2 and PGI2 synthetases. Likewise the addition of chlorine on the para-position on the phenyl ring of I neutralized all its inhibitory effects both on TXA2 and PGI2 synthetases in vitro. None of the 3-amino 4,6-diarylpyridazine derivatives was active on either the TXA2- or PGI2-synthesizing activities of cardiac tissue.